Reproductive and hormonal risk factors for luminal, HER2-overexpressing, and triple-negative breast cancer in Japanese women

Annals of Oncology

Volumn 23, Issue 9, 2012, Pages 2435-2441

  Islam, T ^a,b   Matsuo, K ^a,b   Ito, H ^a   Hosono, S ^a   Watanabe, M ^a   Iwata, H ^a   Tajima, K ^a   Tanaka, H ^a,b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; HER2 overexpressing; Luminal; Menarche; Menopause; Triple negative

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE DERIVATIVE; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST FEEDING; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; JAPANESE; LIVE BIRTH; MAJOR CLINICAL STUDY; MENARCHE; PARITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCTIVE HEALTH; RISK FACTOR; TRIPLE NEGATIVE BREAST CANCER;

EID: 84865553172     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr613     Document Type: Article

References (37)

1. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 15: 2893-2917
2. Ferlay J, Shin HR, Bray F et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer 2010. http://globocan.iarc.fr (10 January 2012, date last accessed).
3. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502.
4. Phipps AI, Malone KE, Porter PL et al. Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008; 17: 2078-2086.
5. Phipps AI, Malone KE, Porter PL et al. Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer 2008; 113: 1521-1526.
6. Yang XR, Sherman ME, Rimm DL et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007; 16: 439-443.
7. Kurebayashi J, Moriya T, Ishida T et al. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 2007; 16(Suppl 2): S72-S77.
8. Sun CL, Yuan JM, Koh WP, Yu MC Green tea, black tea and breast cancer risk: a meta-analysis of epidemiological studies. Carcinogenesis 2006; 27: 1310-1315.
9. Messina M, McCaskill-Stevens W, Lampe JW Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. J Natl Cancer Inst 2006; 98: 1275-1284.
10. Ihemelandu CU, Leffall LD, Jr, Dewitty RL et al. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: agespecific prevalence and survival. J Surg Res 2007; 143: 109-118.
11. Stead LA, Lash TL, Sobieraj JE et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res 2009; 11: R18.
12. Sherman ME, Rimm DL, Yang XR et al. Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: a population-based analysis. Int J Cancer 2007; 121: 1079-1085.
13. Yang XR, Chang-Claude J, Goode EL et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 2011; 103: 250-263.
14. Borresen-Dale AL, Sorlie T, Kristensen VN. On the molecular biology of breast cancer. Mol Oncol 2010; 4: 171-173.
15. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
16. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-10874.
17. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374.
18. Yamashita H, Iwase H, Toyama T et al. Estrogen receptor-positive breast cancer in Japanese women: trends in incidence, characteristics, and prognosis. Ann Oncol 2011; 22: 1318-1325.
19. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993; 15: 36-47.
20. Huang WY, Newman B, Millikan RC et al. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 2000; 151: 703-714.
21. Phipps AI, Buist DS, Malone KE et al. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control 2011; 22: 399-405.
22. Huiyan Ma YW, Sullivan J, Weiss L et al. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. Cancer Res 2010; 70: 575-587.
23. Rosenberg LU, Einarsdottir K, Friman EI et al. Risk factors for hormone receptordefined breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2006; 15: 2482-2488.
24. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a metaanalysis of epidemiological studies. Breast Cancer Res 2006; 8: R43.
25. Xing P, Li J, Jin F. A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China. Med Oncol 2010; 27: 926-931.
26. Inoue M, Tajima K, Hirose K et al. Epidemiological features of first-visit outpatients in Japan: comparison with general population and variation by sex, age, and season. J Clin Epidemiol 1997; 50: 69-77.
27. Kawase T, Matsuo K, Suzuki T et al. Association between vitamin D and calcium intake and breast cancer risk according to menopausal status and receptor status in Japan. Cancer Sci 2010; 101: 1234-1240.
28. Tajima K, Hirose K, Inoue M et al. A model of practical cancer prevention for out-patients visiting a hospital: the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC). Asian Pac J Cancer Prev 2000; 1: 35-47.
29. Hamajima N, Matsuo K, Saito T et al. Gene-environment interactions and polymorphism studies of cancer risk in the Hospital-based Epidemiologic Research Program at Aichi Cancer Center II (HERPACC-II). Asian Pac J Cancer Prev 2001; 2: 99-107.
30. Dawson SJ, Provenzano E, Caldas C. Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer 2009; 45(Suppl 1): 27-40.
31. Brenton JD, Carey LA, Ahmed AA, Caldas C Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J Clin Oncol 2005; 23: 7350-7360.
32. Matsuo K, Wakai K, Hirose K et al. Alcohol dehydrogenase 2 His47Arg polymorphism influences drinking habit independently of aldehyde dehydrogenase 2 Glu487Lys polymorphism: analysis of 2,299 Japanese subjects. Cancer Epidemiol Biomarkers Prev 2006; 15: 1009-1013.
33. Apter D, Vihko R. Early menarche, a risk factor for breast cancer, indicates early onset of ovulatory cycles. J Clin Endocrinol Metab 1983; 57: 82-86.
34. Vihko RK, Apter DL. The epidemiology and endocrinology of the menarche in relation to breast cancer. Cancer Surv 1986; 5: 561-571.
35. Nichols HB, Trentham-Dietz A, Love RR et al. Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. Cancer Epidemiol Biomarkers Prev 2005; 14: 41-47.
36. Millikan RC, Newman B, Tse CK et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008; 109: 123-139.
37. Cheang MC, Voduc D, Bajdik C et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14: 1368-1376.